Education and Training

•1981-1986    B.M., Medicine.TianjinMedical University, China

•2005-2008    M.M.,Oncology, TianjinMedical University, China

Postgraduate Training

•2004-2005visiting scholar,University of Michigan,U.S.A.

Papers

1: Shi Y, Jia Y, Zhao W, Zhou L, Xie X,Tong Z. Histone deacetylase inhibitors

alter the expression of molecular markers in breast cancer cells via microRNAs.

Int J Mol Med. 2018 Jul;42(1):435-442. doi: 10.3892/ijmm.2018.3616. Epub 2018 Apr

3. PubMed PMID: 29620153.

2: Zhao W, Li X, Wang J, Wang C, Jia Y, Yuan S, Huang Y, Shi Y,Tong Z.

Decreasing Eukaryotic Initiation Factor 3C (EIF3C) Suppresses Proliferation and

Stimulates Apoptosis in Breast Cancer Cell Lines Through Mammalian Target of

Rapamycin (mTOR) Pathway. Med Sci Monit. 2017 Aug 30;23:4182-4191. PubMed PMID:

28854163; PubMed Central PMCID: PMC5590544.

3: Gao Y, Ni X, Guo H, Su Z, Ba Y,Tong Z, Guo Z, Yao X, Chen X, Yin J, Yan Z,

Guo L, Liu Y, Bai F, Xie XS, Zhang N. Single-cell sequencing deciphers a

convergent evolution of copy number alterations from primary to circulating tumor

cells. Genome Res. 2017 Aug;27(8):1312-1322. doi: 10.1101/gr.216788.116. Epub

2017 May 9. PubMed PMID: 28487279; PubMed Central PMCID: PMC5538548.

4: Wang S, Li W, Wang F, Niu Y, Hao C, Wang X, He L,Tong Z. 36 cases adenoid

cystic carcinoma of the breast in China: Comparison with matched grade one

invasive ductal carcinoma-not otherwise specified. Pathol Res Pract. 2017

Apr;213(4):310-315. doi: 10.1016/j.prp.2017.01.021. Epub 2017 Jan 31. PubMed

PMID: 28222936.

5: Zhang P, Sun T, Zhang Q, Yuan Z, Jiang Z, Wang XJ, Cui S, Teng Y, Hu XC, Yang

J, Pan H,Tong Z, Li H, Yao Q, Wang Y, Yin Y, Sun P, Zheng H, Cheng J, Lu J,

Zhang B, Geng C, Liu J, Peng R, Yan M, Zhang S, Huang J, Tang L, Qiu R, Xu B;

BG01-1323L study group. Utidelone plus capecitabine versus capecitabine alone for

heavily pretreated metastatic breast cancer refractory to anthracyclines and

taxanes: a multicentre, open-label, superiority, phase 3, randomised controlled

trial. Lancet Oncol. 2017 Mar;18(3):371-383. doi: 10.1016/S1470-2045(17)30088-8.

Epub 2017 Feb 11. PubMed PMID: 28209298.

6: Zhang P,Tong Z, Tian F, Wang Y, Yang J, Li W, Di L, Liu W, Tang L, Qiu R, Xu

B. Phase II trial of utidelone as monotherapy or in combination with capecitabine

in heavily pretreated metastatic breast cancer patients. J Hematol Oncol. 2016

Aug 11;9(1):68. doi: 10.1186/s13045-016-0297-7. PubMed PMID: 27516093; PubMed

Central PMCID: PMC4982136.

7: Zhang Q, Shao Z, Shen K, Li L, Feng J,Tong Z, Gu K, Wang X, Xu B, Sun G, Chen

H, Rukazenkov Y, Jiang Z. Fulvestrant 500 mg vs 250 mg in postmenopausal women

with estrogen receptor-positive advanced breast cancer: a randomized,

double-blind registrational trial in China. Oncotarget. 2016 Aug

30;7(35):57301-57309. doi: 10.18632/oncotarget.10254. PubMed PMID: 27359058;

PubMed Central PMCID: PMC5302990.

8: Zhang L, Wu Y, Liu F, Fu L,Tong Z. Characteristics and survival of patients

with metachronous or synchronous double primary malignancies: breast and thyroid

cancer. Oncotarget. 2016 Aug 9;7(32):52450-52459. doi: 10.18632/oncotarget.9547.

PubMed PMID: 27223440; PubMed Central PMCID: PMC5239566.

9: Yang M, Liu F, Higuchi K, Sawashita J, Fu X, Zhang L, Zhang L, Fu L,Tong Z,

Higuchi K. Serum amyloid A expression in the breast cancer tissue is associated

with poor prognosis. Oncotarget. 2016 Jun 14;7(24):35843-35852. doi:

10.18632/oncotarget.8561. PubMed PMID: 27058895; PubMed Central PMCID:

PMC5094967.

10: Xu B, Tian F, Yu J, Song Y, Shi J, Zhang B, Zhang Y, Yuan Z, Wu Q, Zhang Q,

Nan K, Sun Q, Li W, Hu J, Bi J, Meng C, Dai H, Jiang H, Yue S, Cao B, Sun Y, Wang

S,Tong Z, Shen P, Wu G, Tang L, Deng Y, Jia L, Shen K, Zhuang W, Xie X, Wu Y,

Chen L. [A multicenter, randomized, controlled, phaseⅢclinical study of

PEG-rhG-CSF for preventing chemotherapy-induced neutropenia in patients with

breast cancer and non-small cell lung cancer]. Zhonghua Zhong Liu Za Zhi. 2016

Jan;38(1):23-7. doi: 10.3760/cma.j.issn.0253-3766.2016.01.005. Chinese. PubMed

PMID: 26796802.

11: Zhao W, Wang J, Zhu B, Duan Y, Chen F, Nian W, Sun J, Zhang B,Tong Z, Chen

Z. IGFBP7 functions as a potential lymphangiogenesis inducer in non-small cell

lung carcinoma. Oncol Rep. 2016 Mar;35(3):1483-92. doi: 10.3892/or.2015.4516.

Epub 2015 Dec 24. PubMed PMID: 26706909.

12: Zheng L, Wang J, Zhang J, Song Z, Dong Y, Wang Y,Tong Z, Deng C, Yin Y, Meng

M, Xi R. Preparation of polyclonal antibodies for nateglinide (NTG) and

development of a sensitive chemiluminescent immunoassay to detect NTG in tablets

and serum. Talanta. 2016;146:483-9. doi: 10.1016/j.talanta.2015.09.008. Epub 2015

Sep 9. PubMed PMID: 26695294.

13: Wang C, Ju H, Shen C,Tong Z. miR-429 mediates δ-tocotrienol-induced

apoptosis in triple-negative breast cancer cells by targeting XIAP. Int J Clin

Exp Med. 2015 Sep 15;8(9):15648-56. eCollection 2015. PubMed PMID: 26629059;

PubMed Central PMCID: PMC4658948.

14: Jia Y, Zhou L, Tian C, Shi Y, Wang C,Tong Z. Dynamin-related protein 1 is

involved in micheliolide-induced breast cancer cell death. Onco Targets Ther.

2015 Nov 16;8:3371-81. doi: 10.2147/OTT.S91805. eCollection 2015. PubMed PMID:

26622184; PubMed Central PMCID: PMC4654538.

15: Xu B, Hu X, Jiang Z, Li H, Chen J, Cui S, Li Q, Liao N, Liu D, Liu J, Lu J,

Shen K, Sun T, Teng Y,Tong Z, Wang S, Wang X, Wang X, Wang Y, Wu J, Yuan P,

Zhang P, Zhang Q, Zheng H, Pang D, Ren G, Shao Z, Shen Z, Song E, Song S.

National consensus in China on diagnosis and treatment of patients with advanced

breast cancer. Ann Transl Med. 2015 Oct;3(17):242. doi:

10.3978/j.issn.2305-5839.2015.09.47. Review. PubMed PMID: 26605288; PubMed

Central PMCID: PMC4620095.

16: Lu N,Tong Z, Zhang M, Lu L, Cao H. [Effect and mechanism of EGFR expression

in macrophages on the anti-cancer effect of berberine on colorectal cancer].

Zhonghua Zhong Liu Za Zhi. 2015 May;37(5):342-6. Chinese. PubMed PMID: 26463023.

17: Jia Y, Zhang C, Zhou L, Xu H, Shi Y,Tong Z. Micheliolide overcomes

KLF4-mediated cisplatin resistance in breast cancer cells by downregulating

glutathione. Onco Targets Ther. 2015 Aug 28;8:2319-27. doi: 10.2147/OTT.S88661.

eCollection 2015. PubMed PMID: 26356142; PubMed Central PMCID: PMC4559251.

18: Dong G, Jia Y, Wang X, Li S, Wang C, Shi Y,Tong Z. The comparison of

maintenance treatment with capecitabine (CMT) and non-maintenance treatment with

capecitabine (non-CMT) in patients with metastatic breast cancer. Int J Clin Exp

Med. 2015 May 15;8(5):8283-7. eCollection 2015. PubMed PMID: 26221411; PubMed

Central PMCID: PMC4509356.

19: Dong Y, Zhang J, Xing Y, Song Z, Wang Y, Meng M, Deng C,Tong Z, Yin Y, Xi R.

Quantification of Ponceau 4R in Foods by Indirect Competitive Enzyme-Linked

Immunosorbent Assay (icELISA). J Agric Food Chem. 2015 Jul 22;63(28):6338-45.

doi: 10.1021/acs.jafc.5b02129. Epub 2015 Jul 14. PubMed PMID: 26138666.

20: Wang C, Husain K, Zhang A, Centeno BA, Chen DT,Tong Z, Sebti SM, Malafa MP.

EGR-1/Bax pathway plays a role in vitamin E δ-tocotrienol-induced apoptosis in

pancreatic cancer cells. J Nutr Biochem. 2015 Aug;26(8):797-807. doi:

10.1016/j.jnutbio.2015.02.008. Epub 2015 Apr 1. PubMed PMID: 25997867; PubMed

Central PMCID: PMC4576995.

21: Wang F, Jia Y,Tong Z. Comparison of the clinical and prognostic features of

primary breast sarcomas and malignant phyllodes tumor. Jpn J Clin Oncol. 2015

Feb;45(2):146-52. doi: 10.1093/jjco/hyu177. Epub 2014 Nov 11. PubMed PMID:

25387733.

22: Lu C, Wang W, Jia Y, Liu X,Tong Z, Li B. Inhibition of AMPK/autophagy

potentiates parthenolide-induced apoptosis in human breast cancer cells. J Cell

Biochem. 2014 Aug;115(8):1458-66. doi: 10.1002/jcb.24808. PubMed PMID: 24619908.

23: Wang X, Wang W, Lin Z, Wang X, Li T, Yu J, Liu W,Tong Z, Xu Y, Zhang J, Guan

L, Dai L, Yang Y, Han W, Li R. CARD9 mutations linked to subcutaneous

phaeohyphomycosis and TH17 cell deficiencies. J Allergy Clin Immunol. 2014

Mar;133(3):905-8.e3. doi: 10.1016/j.jaci.2013.09.033. Epub 2013 Nov 11. PubMed

PMID: 24231284.

24: Chen X, Liu X, Zhang L, Li S, Shi Y,Tong Z. Poorer survival of male breast

cancer compared with female breast cancer patients may be due to biological

differences. Jpn J Clin Oncol. 2013 Oct;43(10):954-63. doi: 10.1093/jjco/hyt116.

Epub 2013 Aug 9. PubMed PMID: 23935206.